Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment.

Johnson MH, Nepple KG, Peck V, Trinkaus K, Klim A, Sandhu GS, Kibel AS.

J Urol. 2013 Apr;189(4):1268-74. doi: 10.1016/j.juro.2012.10.070. Epub 2012 Oct 30.

2.

The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.

Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, Shariat SF, Chun F.

J Urol. 2013 Sep;190(3):857-62. doi: 10.1016/j.juro.2013.03.097. Epub 2013 Mar 29.

PMID:
23545101
4.

Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.

Nepple KG, Lightfoot AJ, Rosevear HM, O'Donnell MA, Lamm DL; Bladder Cancer Genitourinary Oncology Study Group..

J Urol. 2010 Nov;184(5):1915-9. doi: 10.1016/j.juro.2010.06.147. Epub 2010 Sep 17.

PMID:
20846688
5.

Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.

Miyazaki J, Hinotsu S, Ishizuka N, Naito S, Ozono S, Akaza H, Nishiyama H.

Jpn J Clin Oncol. 2013 Aug;43(8):827-34. doi: 10.1093/jjco/hyt086. Epub 2013 Jul 14.

PMID:
23858038
6.

Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.

Yokomizo A, Kanimoto Y, Okamura T, Ozono S, Koga H, Iwamura M, Tanaka H, Takahashi S, Tsushima T, Kanayama HO, Akaza H, Shinohara N, Mugiya S, Nomata K, Nakamura T, Naito S.

J Urol. 2016 Jan;195(1):41-6. doi: 10.1016/j.juro.2015.08.075. Epub 2015 Aug 22.

PMID:
26307162
7.

The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study.

Pan CW, Shen ZJ, Ding GQ.

J Urol. 2008 Apr;179(4):1307-11; discussion 1311-2. doi: 10.1016/j.juro.2007.11.045. Epub 2008 Mar 4.

PMID:
18289576
8.

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.

Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, de Reijke TM; EORTC Genito-Urinary Tract Cancer Group..

Eur Urol. 2010 May;57(5):766-73. doi: 10.1016/j.eururo.2009.12.024. Epub 2009 Dec 18.

9.

[Calmette-Guerin bacillus disseminated infection after intravesical instillation].

Borré S, Brustia D, Rosa F, Brondolo R, Rizzo G, Garavelli PL.

Recenti Prog Med. 2002 Apr;93(4):247-8. Review. Italian.

PMID:
11989131
10.

Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.

Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P.

J Urol. 1990 Mar;143(3):502-6.

PMID:
2106041
11.

Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices.

Rosevear HM, Lightfoot AJ, Nepple KG, O'Donnell MA.

J Urol. 2010 Nov;184(5):1920-4. doi: 10.1016/j.juro.2010.06.149. Epub 2010 Sep 17.

PMID:
20846678
12.

Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study.

Pfister C, Kerkeni W, Rigaud J, Le Gal S, Saint F, Colombel M, Guy L, Wallerand H, Irani J, Soulie M; Cancer Committee of French Urological Association..

Int J Urol. 2015 Jan;22(1):53-60. doi: 10.1111/iju.12609. Epub 2014 Sep 25.

13.

Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.

Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni G.

J Urol. 2006 Aug;176(2):482-5.

PMID:
16813873
14.

Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy.

Ozbakkaloglu B, Tünger O, Sürücüoglu S, Lekili M, Kandiloglu AR.

Int Urol Nephrol. 1999;31(1):49-53.

PMID:
10408303
15.

Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.

Tozawa K, Okamura T, Sasaki S, Kawai N, Ito Y, Hayashi Y, Kohri K.

Urol Int. 2001;67(4):289-92.

PMID:
11741130
16.

Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer.

Ferrari KL, de Camargo JA, Rocha GZ, Carvalheira JB, Saad MJ, Billis A, Reis LO.

J Urol. 2015 Feb;193(2):682-9. doi: 10.1016/j.juro.2014.08.106. Epub 2014 Sep 6.

PMID:
25200808
17.

Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus Calmette-Guerin or placebo.

Propert KJ, Mayer R, Nickel JC, Payne CK, Peters KM, Teal V, Burks D, Kusek JW, Nyberg LM, Foster HE; Interstitial Cystitis Clinical Trials Group..

J Urol. 2008 Feb;179(2):552-5. Epub 2007 Dec 21.

18.

Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.

Cai T, Nesi G, Tinacci G, Zini E, Mondaini N, Boddi V, Mazzoli S, Bartoletti R.

J Urol. 2008 Jul;180(1):110-5. doi: 10.1016/j.juro.2008.03.038. Epub 2008 May 15.

PMID:
18485394
19.

Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria.

Herr HW.

J Urol. 2012 Feb;187(2):435-7. doi: 10.1016/j.juro.2011.10.032. Epub 2011 Dec 15.

PMID:
22177154
20.

A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.

Lamm DL, DeHaven JI, Shriver J, Crispen R, Grau D, Sarosdy MF.

J Urol. 1990 Jul;144(1):65-7.

PMID:
2193172

Supplemental Content

Support Center